Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Richa Rai, PhD, Foramben Patel, MS, Stella Melana, PhD, Jonathan Feld, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142908

Published: 2020

Journal Articles

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4231.

https://doi.org/10.1182/blood-2019-130747

Published: 2019

Journal Articles

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2018-99-119266

Published: 2018

Journal Articles

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Lewis R Silverman, MD, Pratima Chaurasia, PhD, Stella Melana, PhD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, BA, BSN, MSN, RN, Shyamala C. Navada, MD, E. Premkumar Reddy, PhD BSc, MSc

Blood (2017) 130 (Supplement 1): 4235.

https://doi.org/10.1182/blood.V130.Suppl_1.4235.4235

Published: 2017

Journal Articles

Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition

Deepak Perumal, PhD, Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, Zewei Jiang, MD, Ben Readhead, MBBS, Caroline Eden, BS, Sai Krishna Athaluri Divakar, PhD, Weijia Zhang, PhD, Hearn Jay Cho, MD PhD, Ajai Chari, MD, M.V.Ramana Reddy, PhD, E. Premkumar Reddy, PhD, Joel Dudley, PhD, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2014) 124 (21): 3445.

https://doi.org/10.1182/blood.V124.21.3445.3445

Published: 2014

Journal Articles

Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins

E. Premkumar Reddy, PhD, Sai Krishna Divakar, PhD, Rodrigo Vasquez-Del Carpio, PhD, Kaushik Dutta, PhD, Stacey J Baker, PhD, Ramana Reddy, PhD, Aneel K Aggarwal, PhD

Blood (2014) 124 (21): 5616.

https://doi.org/10.1182/blood.V124.21.5616.5616

Published: 2014

Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2013) 122 (21): 1527.

https://doi.org/10.1182/blood.V122.21.1527.1527

Published: 2013

Journal Articles

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2012) 120 (21): 3794.

https://doi.org/10.1182/blood.V120.21.3794.3794

Published: 2012

Journal Articles

An In Vivo Functional Screen Identifies miRNA-150 As a Regulator of Hematopoietic Regeneration Post Chemotherapeutic Injury

Brian D. Adams, PhD, Shangqin Guo, PhD, Haitao Bai, MD, Changchun Xiao, PhD, E. Premkumar Reddy, PhD, Jun Lu, PhD

Blood (2011) 118 (21): 2333.

https://doi.org/10.1182/blood.V118.21.2333.2333

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

David M. Soper, PhD, Ying-Wen Huang, MS, Francois Wilhelm, MD, Ph.D, S. C. Cosenza, E. Premkumar Reddy, PhD, Alessandra Cesano, MD, PhD, Peter L Greenberg, MD, Wendy J. Fantl, PhD

Blood (2009) 114 (22): 3827.

https://doi.org/10.1182/blood.V114.22.3827.3827

Published: 2009

Journal Articles

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

Lewis R. Silverman, MD, Rosalie Odchimar-Reissig, Shyamala C. Navada, MD, Takao Ohnuma, MD, Vesna Najfeld, Ph.D., Francois Wilhelm, MD, Ph.D, E. Premkumar Reddy, PhD, James F Holland

Blood (2009) 114 (22): 4839.

https://doi.org/10.1182/blood.V114.22.4839.4839

Published: 2009

Journal Articles

Suppression of Cyclin D1 by on 01910.Na Is Associated with Decreased Survival of Trisomy 8 Myelodyplastic Bone Marrow Progenitors: A Potential Targetted Therapy.

Elaine M. Sloand, MD, Loretta Pfannes, Ramana Reddy, PhD, Premkumar Reddy, PhD, Jerome S. Groopman, MD, Neal S. Young, MD

Blood (2007) 110 (11): 822.

https://doi.org/10.1182/blood.V110.11.822.822

Published: 2007

NARROW

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition

Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

An In Vivo Functional Screen Identifies miRNA-150 As a Regulator of Hematopoietic Regeneration Post Chemotherapeutic Injury

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

Suppression of Cyclin D1 by on 01910.Na Is Associated with Decreased Survival of Trisomy 8 Myelodyplastic Bone Marrow Progenitors: A Potential Targetted Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only